Compare ONEG & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONEG | NEPH |
|---|---|---|
| Founded | 2021 | 1997 |
| Country | Hong Kong | United States |
| Employees | 26 | N/A |
| Industry | Homebuilding | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.3M | 31.0M |
| IPO Year | N/A | 2004 |
| Metric | ONEG | NEPH |
|---|---|---|
| Price | $10.83 | $3.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 1.5M | 21.0K |
| Earning Date | 01-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1000.00 |
| EPS | N/A | ★ 0.11 |
| Revenue | N/A | ★ $18,789,000.00 |
| Revenue This Year | N/A | $11.24 |
| Revenue Next Year | N/A | $11.58 |
| P/E Ratio | ★ N/A | $27.87 |
| Revenue Growth | N/A | ★ 32.67 |
| 52 Week Low | $0.96 | $1.88 |
| 52 Week High | $13.50 | $6.42 |
| Indicator | ONEG | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 95.74 | 50.21 |
| Support Level | $10.26 | $2.77 |
| Resistance Level | $12.04 | $3.18 |
| Average True Range (ATR) | 1.13 | 0.24 |
| MACD | 0.50 | 0.04 |
| Stochastic Oscillator | 62.71 | 60.44 |
OneConstruction Group Ltd is a structural steelwork contractor in Hong Kong. The company is engaged in the procurement and installation of structural steel for construction projects in Hong Kong. Its construction project includes performing site preparatory and preliminary works, developing detailed work schedules and work allocation plans, implementing construction site works, and conducting site safety supervision and quality control.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.